Fliser Danilo, Novak Jan, Thongboonkerd Visith, Argilés Angel, Jankowski Vera, Girolami Mark A, Jankowski Joachim, Mischak Harald
Mosaiques Diagnostics and Therapeutics AG, Mellendorfer Strasse 7-9, D-30625 Hannover, Germany.
J Am Soc Nephrol. 2007 Apr;18(4):1057-71. doi: 10.1681/ASN.2006090956. Epub 2007 Feb 28.
Noninvasive diagnosis of kidney diseases and assessment of the prognosis are still challenges in clinical nephrology. Definition of biomarkers on the basis of proteome analysis, especially of the urine, has advanced recently and may provide new tools to solve those challenges. This article highlights the most promising technological approaches toward deciphering the human proteome and applications of the knowledge in clinical nephrology, with emphasis on the urinary proteome. The data in the current literature indicate that although a thorough investigation of the entire urinary proteome is still a distant goal, clinical applications are already available. Progress in the analysis of human proteome in health and disease will depend more on the standardization of data and availability of suitable bioinformatics and software solutions than on new technological advances. It is predicted that proteomics will play an important role in clinical nephrology in the very near future and that this progress will require interactive dialogue and collaboration between clinicians and analytical specialists.
肾脏疾病的无创诊断及预后评估仍是临床肾脏病学面临的挑战。基于蛋白质组分析，尤其是尿液蛋白质组分析来定义生物标志物，近年来取得了进展，可能为解决这些挑战提供新工具。本文重点介绍了解析人类蛋白质组最具前景的技术方法及其在临床肾脏病学中的应用，尤其关注尿液蛋白质组。当前文献中的数据表明，尽管对整个尿液蛋白质组进行全面研究仍是一个遥远的目标，但临床应用已经存在。健康和疾病状态下人类蛋白质组分析的进展将更多地取决于数据的标准化以及合适的生物信息学和软件解决方案的可用性，而非新技术的进步。预计蛋白质组学将在不久的将来在临床肾脏病学中发挥重要作用，而这一进展将需要临床医生和分析专家之间的互动对话与合作。
